PubMed Health⌕ Search

PubMed · 7455122

Computed tomography in hepatic lymphoma.

Abstract

Computed tomographic (CT) examinations of the abdomen, performed in 323 patients with lymphoma, were reviewed to determine the value of CT in detecting lymphomatous involvement of the liver and the CT appearance of hepatic lymphoma. Additionally, the CT scans were compared with the radionuclide scans. Of 95 patients in whom histological studies were performed, 65 had undergone both CT and radionuclide scanning. CT was found to have a sensitivity of 57% and a specificity of 88%. Radionuclide scans had a sensitivity of 71% and a specificity of 81%. No specific pattern of involvement was revealed by CT. No correlation was found between the type of lymphoma and evidence of liver involvement on CT or radionuclide scans. The results of studies of the spleen are also briefly reviewed. False-positive results of CT examinations were usually the result of technical artifacts. CT and radionuclide scans are comparable in their ability to detect hepatic involvement by lymphoma; however, because CT also provides information on abdominal lymph nodes, it is the preferable examination.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Zornoza, S Ginaldi. 1981. Computed tomography in hepatic lymphoma.. https://doi.org/10.1148/radiology.138.2.7455122

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.

The transcription factor NF-kappaB is a tightly regulated positive mediator of T- and B-cell development, proliferation, and survival. The controlled activity of NF-kappaB is required for the coordination of physiologic immune responses. However, constitutive NF-kappaB activation can promote continuous lymphocyte proliferation and survival and has recently been recognized as a critical pathogenetic factor in lymphoma. Various molecular events lead to deregulation of NF-kappaB signaling in Hodgkin disease and a variety of T- and B-cell non-Hodgkin lymphomas either up-stream or downstream of the central IkappaB kinase. These alterations are prerequisites for lymphoma cell cycling and blockage of apoptosis. This review provides an overview of the NF-kappaB pathway and discusses the mechanisms of NF-kappaB deregulation in distinct lymphoma entities with defined aberrant pathways: Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), mucosa-associated lymphoid tissue (MALT) lymphoma, primary effusion lymphoma (PEL), and adult T-cell lymphoma/leukemia (ATL). In addition, we summarize recent data that validates the NF-kappaB signaling pathway as an attractive therapeutic target in T- and B-cell malignancies.

Hodgkin Disease↗